Monoclonal antibodies against PD-1, PD-L1 yield significant clinical benefit for lung cancer patients by inhibiting immune checkpoint activity, but clinical predictors of response to these therapies remain incompletely characterized. The gene discussed is PDCD1; the disease is lung carcinoma.